These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15449905)

  • 1. [Recent progress in anti-HIM-1 research].
    Baba M
    Uirusu; 2004 Jun; 54(1):59-66. PubMed ID: 15449905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 antiretroviral drug therapy.
    Arts EJ; Hazuda DJ
    Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiretroviral drugs.
    Gulick RM
    Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.
    Barbaro G; Scozzafava A; Mastrolorenzo A; Supuran CT
    Curr Pharm Des; 2005; 11(14):1805-43. PubMed ID: 15892677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
    Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
    Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in anti-HIV chemotherapy.
    De Clercq E
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):258-75. PubMed ID: 12084468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
    Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
    J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS: recent advances in antiretroviral agents.
    Nikolopoulos G; Bonovas S; Tsantes A; Sitaras NM
    Mini Rev Med Chem; 2009 Jul; 9(8):900-10. PubMed ID: 19601885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The newest developments in anti-HIV-1 drugs].
    Zhang XQ
    Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of HIV antiretroviral drug resistance.
    Chen TK; Aldrovandi GM
    Pediatr Infect Dis J; 2008 Aug; 27(8):749-52. PubMed ID: 18664987
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro.
    Tremblay CL; Giguel F; Kollmann C; Guan Y; Chou TC; Baroudy BM; Hirsch MS
    Antimicrob Agents Chemother; 2002 May; 46(5):1336-9. PubMed ID: 11959565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in small molecule CCR5 antagonists as potential HIV-1 entry inhibitors.
    Chen W; Zhan P; De Clercq E; Liu X
    Curr Pharm Des; 2012; 18(1):100-12. PubMed ID: 22236118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.